Biotech Leader NeuraClick Appoints Industry Veteran Daniel M. Bradbury To Guide Strategic And Metabolic Programs

NeuraClick, Inc., a preclinical-stage biopharmaceutical company focused on developing innovative, long-acting neurotherapeutics to improve patient health, has announced the appointment of Daniel M. Bradbury as Strategic and Metabolic Programs Advisor. Bradbury is a highly experienced industry leader with more than 40 years in the life sciences sector. He has successfully guided global biopharmaceutical businesses, advanced new medicines to market, and played a key role in driving corporate growth.

Dr. Subhi Marwari, Chief Executive Officer, stated, “We are thrilled to welcome Dan to NeuraClick. For an early-stage venture, experienced guidance is essential, and Dan’s deep expertise in company building and metabolic therapeutics will be invaluable as we advance our pipeline. He is a phenomenal coach on this journey, helping us navigate the complexities of developing transformative treatments for patients facing serious medical conditions. We are also building a team of scientific and strategic advisors with exceptional track records who share our mission to deliver breakthrough medicines that are highly effective, safer, and transformative for patients’ lives, while driving long-term shareholder value.”

Dan Bradbury, mentioned, “I am excited to support NeuraClick’s mission to address urgent challenges in neuropsychiatric care and metabolic disorders. The company’s approach – harnessing the best of natural biology combined with cutting-edge chemical technology – has the potential to truly transform how we understand and experience disease. Nature holds remarkable power to provide the best solutions, and I look forward to contributing my experience to help advance its science toward clinical care and accelerate its growth.”

He currently serves as the Executive Chairman and Co-Founder of Equillium, Inc., and is the Managing Member of BioBrit, LLC, a prominent life sciences consulting and investment firm. Previously, Bradbury was the CEO of Amylin Pharmaceuticals, where he led the company through a period of substantial growth and its acquisition by Bristol Myers Squibb. In addition to these roles, he serves on the boards of and advises several biotechnology companies, bringing deep expertise and strategic insight to NeuraClick’s efforts.